Nucleic Acids Research, 2003, Vol. 31, No. 15 4354-4360
© 2003 Oxford University Press
Intracellular mRNA cleavage by 3' tRNase under the direction of 2'-O-methyl RNA heptamers
Department of Biochemistry, Kagoshima University Dental School, Kagoshima, Kagoshima 890-8544, Japan, 1 Biological Function Division, National Food Research Institute, Tsukuba, Ibaraki 305-8642 Japan and 2 Department of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niitsu, Niigata 956-8603, Japan
*To whom correspondence should be addressed at Department of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, Higashijima 265-1, Niitsu, Niigata 956-8603, Japan. Tel: +81 250 25 5119; Fax: +81 250 25 5021; Email: mnashimoto{at}niigatayakudai.jp
Mammalian tRNA 3' processing endoribonuclease (3'-tRNase) can cleave any RNA at any site under the direction of small guide RNA (sgRNA) in vitro. sgRNAs can be as short as heptamers, which are much smaller than small interfering RNAs of 
21 nt. Together with such flexibility in substrate recognition, the ubiquity and the constitutive expression of 3'-tRNase have suggested that this enzyme can be utilized for specific cleavage of cellular RNAs by introducing appropriate sgRNAs into living cells. Here we demonstrated that the expression of chloramphenicol acetyltransferase can be downregulated by an appropriate sgRNA which is introduced into Madin–Darby canine kidney epithelial cells as an expression plasmid or a synthetic 2'-O-methyl RNA. We also showed that 2'-O-methyl RNA heptamers can attack luciferase mRNAs with a high specificity and induce 3'-tRNase-mediated knock-down of the mRNAs in 293 cells. Furthermore, the MTT cell viability assay suggested that an RNA heptamer can downregulate the endogenous Bcl-2 mRNA in Sarcoma 180 cells. This novel sgRNA/3'-tRNase strategy for destroying specific cellular RNAs may be utilized for therapeutic applications.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. M. Sato, A. Nakashima, M. Nashimoto, Y. Yawaka, and M. Tamura Bone morphogenetic protein-2 enhances Wnt/beta-catenin signaling-induced osteoprotegerin expression. Genes Cells, February 1, 2009; 14(2): 141 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Scherer, R. Frank, and J. J. Rossi Optimization and characterization of tRNA-shRNA expression constructs Nucleic Acids Res., April 10, 2007; (2007) gkm103v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Shibata, H. Takaku, M. Takagi, and M. Nashimoto The T Loop Structure Is Dispensable for Substrate Recognition by tRNase ZL J. Biol. Chem., June 10, 2005; 280(23): 22326 - 22334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Habu, N. Miyano-Kurosaki, M. Kitano, Y. Endo, M. Yukita, S. Ohira, H. Takaku, M. Nashimoto, and H. Takaku Inhibition of HIV-1 gene expression by retroviral vector-mediated small-guide RNAs that direct specific RNA cleavage by tRNase ZL Nucleic Acids Res., January 12, 2005; 33(1): 235 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takaku, A. Minagawa, M. Takagi, and M. Nashimoto The N-terminal half-domain of the long form of tRNase Z is required for the RNase 65 activity Nucleic Acids Res., August 18, 2004; 32(15): 4429 - 4438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takaku, A. Minagawa, M. Takagi, and M. Nashimoto A novel 4-base-recognizing RNA cutter that can remove the single 3' terminal nucleotides from RNA molecules Nucleic Acids Res., June 28, 2004; 32(11): e91 - e91. [Abstract] [Full Text] [PDF]
|
|